Lumbar spine bone mineral density response rates in a study of recombinant human parathyroid hormone (1-34) compared to alendronate sodium in postmenopausal women with osteoporosis.

被引：0
|
作者：
Kulkarni, PM
Gaich, GA
Scheele, WH
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2001年 / 44卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1960
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 50 条
  • [41] Comparison of dose, drug concentrations, and biochemical markers of bone turnover as predictors of bone mineral density response to LY333334 [rhPTH(1-34)] in women with osteoporosis.
    Satterwhite, JH
    Melnick, KA
    O'Brien, LM
    Gaich, GA
    Heathman, MA
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S230 - S230
  • [42] RETRACTED: Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis (Retracted Article)
    Iwamoto, Jun
    Takeda, Tsuyoshi
    Sato, Yoshihiro
    Uzawa, Mitsuyoshi
    [J]. CLINICAL RHEUMATOLOGY, 2007, 26 (02) : 161 - 167
  • [43] Comparison of Efficacy of Teriparatide (Parathyroid Hormone 1-34) Alone and in Combination with Zoledronic Acid for Osteoporosis in Postmenopausal Women
    Wei, Kang
    Qu, Yuxing
    Gao, Yi
    Ma, Yong
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (02): : 240 - 242
  • [44] Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
    Stock, JL
    Bell, NH
    Chesnut, CH
    Ensrud, KE
    Genant, HK
    Harris, ST
    McClung, MR
    Singer, FR
    Yood, RA
    PryorTillotson, S
    Wei, L
    Santora, AC
    [J]. AMERICAN JOURNAL OF MEDICINE, 1997, 103 (04): : 291 - 297
  • [45] Recombinant Human Parathyroid Hormone Related Protein 1-34 and 1-84 and Their Roles in Osteoporosis Treatment
    Wang, Hua
    Liu, Jingning
    Yin, Ying
    Wu, Jun
    Wang, Zilu
    Miao, Dengshun
    Sun, Wen
    [J]. PLOS ONE, 2014, 9 (02):
  • [46] Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis - Results from a placebo-controlled randomized trial.
    Roe, EB
    Sanchez, SD
    del Puerto, GA
    Pierini, E
    Bacchetti, P
    Cann, CE
    Arnaud, CD
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S137 - S137
  • [47] Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber - A dose-response study
    Skripitz, R
    Andreassen, TT
    Aspenberg, P
    [J]. JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2000, 82B (01): : 138 - 141
  • [48] Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis
    Hodsman, AB
    Hanley, DA
    Ettinger, MP
    Bolognese, MA
    Fox, J
    Metcalfe, AJ
    Lindsay, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11): : 5212 - 5220
  • [49] Parathyroid hormone (PTH 1-34) as a treatment for idiopathic osteoporosis in men: Changes in bone mineral density, bone markers, and optimal duration of therapy.
    Kurland, ES
    Cosman, F
    Rosen, CJ
    Lindsay, Z
    Bilezikian, JP
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S230 - S230
  • [50] Retraction Note: Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis
    Jun Iwamoto
    Tsuyoshi Takeda
    Yoshihiro Sato
    Mitsuyoshi Uzawa
    [J]. Clinical Rheumatology, 2021, 40 : 3383 - 3383
12345